Compare AMAL & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMAL | EVO |
|---|---|---|
| Founded | 1923 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 934.1M |
| IPO Year | 2020 | N/A |
| Metric | AMAL | EVO |
|---|---|---|
| Price | $41.34 | $3.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $36.00 | $7.00 |
| AVG Volume (30 Days) | ★ 106.7K | 85.0K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | $1.37 |
| Revenue Next Year | $6.55 | $10.05 |
| P/E Ratio | $49.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.13 | $2.31 |
| 52 Week High | $44.01 | $4.48 |
| Indicator | AMAL | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 53.04 |
| Support Level | $36.50 | $2.88 |
| Resistance Level | $42.70 | $3.36 |
| Average True Range (ATR) | 1.09 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 54.98 | 54.34 |
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.